Primary Breast Cancer
Conditions
Keywords
alopecia, scalp cooling system, cold cap
Brief summary
This is a phase III, single-center, prospective, open-label, randomized,controlled study
Detailed description
To conduct a prospective randomized controlled study comparing the effect of scalp cooling system (DigniCap) and chemical cold cap on preventing chemotherapy-induced alopecia in a group of breast cancer patients receiving standard anthracycline followed paclitaxel regimens. To obtain the exact data on the role of different methods of preventing alopecia in Chinese women with breast cancer. PASS 11 software was used to calculate the sample size. According to the results of previous studies, the hair retention rate of the cold cap group was 67.7%, the hair retention rate of the scalp cooling system group was 50.5%, α=0.05，Power=0.8. The sample size was calculated to be at least 128 cases in each group, 256 cases in total.
Interventions
DEVICEScalp cooling system
Scalp cooling was initiated 30 minutes prior to each chemotherapy cycle, with scalp temperature maintained at 3°C (37°F) throughout chemotherapy and for 90 minutes to 120 minutes afterward. Temperature of scalp cooling system can be controlled constantly, the effect of reducing scalp temperature maybe better and patient tolerance maybe better. Meanwhile, there is a higher likelihood of hair retention due to a tight fit in scalp cooling system.
DEVICECold cap
The operation of chemical cold cap is convenient and the price was low, and the economic burden of patients was not increased. But it is necessary to replace the cold cap periodically during chemotherapy, and the temperature during chemotherapy is difficult to keep constant.
Sponsors
Tao OUYANG
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Female patients, 18≦age ≦66 years * Invasive breast cancer diagnosed with core needle needle biopsy * Staging I-II * Without chemotherapy contraindications, and planned to receive neoadjuvant chemotherapy with a standard regimen (containing 4-cycle dose-dense anthracycline followed 4-cycle paclitaxel) * Attend the study voluntarily, sign the informed consent
Exclusion criteria
* History of malignant tumors * With chemotherapy contraindications * With severe dermatosis and severe sparsity * History of chronic diseases such as cerebrovascular disease, migraine and hyperthyroidism * Uncontrolled diseases(e.g., heart failure, myocardial infarction within 6 months, arrhythmia, unstable diabetes, hypercalcemia) or active infection * Refuse to join the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The effects on the prevention of alopecia of two methods | One year after neoadjuvant chemotherapy | To compare the effects of scalp cooling system and chemical cold cap on the prevention of chemotherapy-induced alopecia in breast cancer patients undergoing neoadjuvant chemotherapy containing anthracycline followed paclitaxel. To assess hair status, a total of three photographs of patients'hair in the both groups were taken by study personnel before the start of first chemotherapy cycle, within 2 days before the start of paclitaxel chemotherapy and within 1 week after the last chemotherapy cycle. Photographs captured hair from the top of head. Patients assessed and estimated the percentage of hair loss using WHO classification of acute and subacute toxicity of anticancer drugs. Success was defined as WHO criteria alopecia grade I (\<25% hair loss) or grade II (25%-50% hair loss). Failure was defined as WHO criteria alopecia grade III (\>50% hair loss) or grade IV. The primary efficacy end point was assessed by clinicians who were independent. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Qualify of life | One year after neoadjuvant chemotherapy | To compare the effects of scalp cooling system and chemical cold cap on the quality of life. Quality of life was measured using the European Organization for Research and Treatment of Cancer Breast CancerSpecific Quality of Life Questionnaire-Core 30（EORTC QLQ-C30） administered at baseline and at the time of the last chemotherapy cycle. |
| Psychological stress | One year after neoadjuvant chemotherapy | The Hospital Anxiety and Depression Scale (HADS) administered at baseline and at the time of the last chemotherapy cycle was used to assess anxiety and depression. |
Countries
China
Contacts
Primary ContactXinying Yu, Master
Backup ContactYingping Dong, Bachelor
Outcome results
None listed